Please provide your email address to receive an email when new articles are posted on . The FDA has granted priority review to a supplemental new drug application for Linzess for the treatment of ...
The US Food and Drug Administration has expanded its approval of Ironwood Pharmaceuticals' (NASDAQ:IRWD) drug Linzess to include the treatment of functional constipation in children and teens. Linzess ...
Stocktwits on MSN
Why did Ironwood Pharmaceuticals stock skyrocket today?
The outlook assumes net sales for Linzess will be between $1.125 billion and $1.175 billion in FY2026. ・U.S. FDA had approved ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Linzess, the first therapy for pediatric functional constipation in patients aged 6 to 17 ...
FDA has announced it has approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation in adults, according to a news release. Linzess ...
The FDA approved an oral suspension product that combines omeprazole and sodium bicarbonate (Konvomep) to treat benign active gastric ulcers and reduce the risk of upper gastrointestinal bleeds in ...
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that The American Journal of Gastroenterology – the official journal of The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback